Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018 por Ashleigh McGirr, Shehzad M. Iqbal, Jan Olbrecht, Lijoy Varghese

Obter o texto integral

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future por Baudouin Standaert, Christophe Sauboin, Rodrigo DeAntonio, Alen Marijam, Jorge Gomez, Lijoy Varghese, Sharon Zhang

Obter o texto integral

Health economic assessment of a rabies pre-exposure prophylaxis program compared with post-exposure prophylaxis alone in high-risk age groups in the Philippines por Beatriz Quiambao, Lijoy Varghese, Nadia Demarteau, Ruth Faye Sengson, Jenaline Javier, Piyali Mukherjee, Leah Cheryl Manio, Scott Preiss

Obter o texto integral

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany por Desmond Curran, Desirée Van Oorschot, Lijoy Varghese, Lidia Oostvogels, Tomas Mrkvan, Romulo Colindres, Alfred von Krempelhuber, Anastassia Anastassopoulou

Obter o texto integral

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old por Desirée Van Oorschot, Anastassia Anastassopoulou, Barbara Poulsen Nautrup, Lijoy Varghese, Alfred von Krempelhuber, Mohamed Neine, Stéphane Lorenc, Desmond Curran

Obter o texto integral